

Rachael L. Fleurence, PhD

NESTcc Executive Director

April 19, 2018

Establishing the National Evaluation System for health Technology Coordinating Center (NESTcc)

🥑 @NESTccMedTech 🛛 🔲 www.nestcc.org

3

HISTORY OF NEST

The National Evaluation System for health Technology's (NEST) vision is to improve the use of Real-World Evidence (RWE) generated in the routine course of care.





THE ECOSYSTEM CHALLENGE

The health care ecosystem is united behind the need to improve patients' timely access to safe and effective devices as well as to improve the quality of life for patients with medical devices.



NESTcc was developed to tackle the lack of high quality, near real-time, and low cost evidence to support:



Mission

To accelerate the development and translation of new and safe health technologies, leveraging Real-World Evidence (RWE), and innovative research.

Vision

To be the leading organization within the health technology and medical device ecosystem for conducting efficient and timely high-quality Real-World Evidence (RWE) studies throughout the Total Product Life Cycle (TPLC).





What value is NESTcc adding to the ecosystem that is not already there ?

ESTABLISH NESTCC GOVERNANCE

Through an open call for nominations published in January 2017, the inaugural NESTcc Governing Committee was formed.

The NESTcc Governing Committee represents a **diverse set of stakeholder groups**, including:







The NESTcc Governing Committee represents stakeholders across the medical device ecosystem.

NAOMI ARONSON Blue Cross Blue Shield Association (BCBSA)

KATHLEEN BLAKE *American Medical Association (AMA)*

MARK DEEM – MDMA Nominee The Foundry, LLC

PAMELA GOLDBERG *Medical Device Innovation Consortium (MDIC)*

BILL HANLON – ACLA Nominee LabCorp/Covance

ADRIAN HERNANDEZ Duke Clinical Research Institute (DCRI) HARLAN KRUMHOLZ Yale University

ELIZABETH MCGLYNN *Kaiser Permanente*

MICHELLE MCMURRY-HEATH – AdvaMed Nominee Interim Governing Committee Chair Johnson & Johnson Medical Devices

VANCE MOORE *Mercy Health* **JEFFREY SHUREN** FDA, CDRH

SHARON TERRY *Genetic Alliance*

DIANE WURZBURGER – MITA Nominee *GE Healthcare*

MARC BOUTIN National Health Council

TAMARA SYREK JENSEN Center for Clinical Standards and Quality, CMS

Trade Association Nominees



Launching the NESTcc Data Network

DEVELOP NESTCC'S ROLE



NESTcc will develop its role to build a sustainable network of collaborators committed to advancing RWE generation.



DEVELOP NESTCC'S ROLE: DEMONSTRATION PROJECTS



NESTcc is focusing on leveraging RWE in use cases across the total product life cycle.

Principle Investigator(s), Demonstration Project	Pre-Market: Pre-Market Approval, 510(k), De Novo	Label Expansion	Post-Market: including Post- Approval Studies (PAS)	Surveillance	Coverage
Morales, Cronenwett, Thatcher: RAPID	0				
Kong, White, Krucoff: SAFE-STEMI	0				
Dreyer: Lung-RADS	Δ		Δ		
Waters: SHIELD					
Goodney, Sedrakyan: Vascular Implant Networks				0	
Resnic: ICD-DELTA				0	
Dujmovic, Hinrichs, Johnson, Slotwiner: EP PASSION			0		
Atwater & Piccini: Medicare & Implantables			0		
Lampert: mHealth			0		
Johnson & Drozda: EHR-Based Data Network	0				
Ross & Shah: mHealth			0		
	Pre-Market	Regulatory Decis	ion	Post-Market	

Key

Diagnostics

Ability to Support Use Cases Across the Total Product Life Cycle (TPLC)

DEVELOP NESTCC'S ROLE: DEMONSTRATION PROJECTS



NESTcc Demonstration Projects are studies that contribute to the field of RWE within the medical device ecosystem. While ranging in scope and size, Demonstration Projects are expected to:



Develop, verify, and operationalize methods of evidence generation and data use in the pre- and post-market space



Demonstrate scalability across healthcare systems, device types, and manufacturers



Demonstrate impact on patients by stimulating innovation in medical device innovation and decreasing the timeline for development and market launch



Inform NESTcc's strategy as it builds out critical functions and processes for a future sustainable organization

DEVELOP NESTCC'S ROLE: DEMONSTRATION PROJECTS

National Evaluation System for health Technology Coordinating Center

Demonstration Projects derive value across the development of NESTcc, informing NESTcc's strategy and execution.



Leverage

DEVELOP NESTCC'S ROLE: TEST-CASES

NESTcc solicited submissions from industry for RWE test-cases that we will seek to implement with network collaborators.

Test-cases were sought to assess feasibility and are intended to explore the network collaborators' ability to capture the data needed to support a range of studies and analyses.

GOALS OF TEST-CASES

- Solicit test-cases from medical device manufacturers to understand their evidence generation needs
- Explore NESTcc **network collaborators'** ability to capture the data needed to support a range of studies and analyses
- Test and understand the unique capabilities of the NESTcc Data Network
- Assess the **feasibility** of NESTcc's envisioned Data Network





DEVELOP NESTCC'S ROLE: TEST-CASES

NESTcc solicited submissions from industry for RWE test-cases to assess feasibility. Test-cases are intended to explore network collaborators' ability to capture data needed to support a range of studies and analyses.



Submission Deadline -January 31, 2018

NESTcc received **nine test**cases as a result of its Call for Concepts from medical device manufacturers.

Review and Selection – February 2018

Each concept was reviewed by two to four reviewers from MDIC staff and the FDA through objective evaluation criteria. Non-MDIC staff were required to disclose **COI** and sign NDAs with MDIC.

Feasibility Conversations – March and April 2018

NFSTcc network collaborators will be consulted to assess the feasibility of test-cases using Concept Proposals submitted by manufacturers

SNAPSHOT OF TEST-CASES

- ✓ Represent both small and large manufacturers
- ✓ Span the Total Product Life Cycle (TPLC) including pre-market, patient management and clinical guidelines, label expansion, postmarket surveillance, and quality measurement
- ✓ Cover a range of device types including dermatology, cardiovascular, vascular, orthopedics, and surgery







DEVELOP NESTCC'S ROLE: TEST-CASES



To better understand the capabilities of its Data Network, NESTcc is facilitating collaboration between network collaborators and test-case manufacturers, whose de-identified concepts are summarized below:

	TOTAL-PRODUCT LIFE CYCLE (TPLC) ALIGNMENT	PRODUCT(S)	AREA
	Pre-Market Submission	Topical Skin Adhesive	Dermatology
I	Label Expansion	Devices used in Rx of Atrial Fibrillation	Cardiovascular
I	Label Expansion	Stent graft component product	Vascular
	Move from General to Specific Indication	Device used in surgery	Surgery
	Post-market Surveillance	Knee replacement	Orthopedics
I	Post-market Surveillance	Various Devices	Orthopedics
(Patient Management Clinical Guidelines	Anti-coagulation dosage following mechanical heart valve (MHV) replacement	Cardiovascular
(Quality Measurement	Endoscopes	General Hospital Device

DEVELOP NESTCC'S ROLE: TEST-CASES





Engage Leverage Transform

ORTHOPEDIC TEST-CASE EXAMPLE I

- Explore the feasibility of using real world data (RWD) for proactive post-market surveillance that fulfills regulatory obligations (necessary data elements, sufficient sample size, and representativeness of the sample for purposes of generalizability to the patient population of users) for three orthopedic devices.
- The population of interest is patients undergoing craniofacial reconstruction (mostly pediatric patients), spinal decompression/intervertebral body fusion, and ligament/tendon joint attachment.
- ✓ The project will explore proactive surveillance for each device of interest.

ORTHOPEDIC TEST-CASE EXAMPLE II

- Evaluate the feasibility of combining a limited sample of registry data with private claims payments from NESTcc network collaborators.
- Project will look at primary total knee replacement surgical procedures and implants in younger (<65 years of age) patients.
- Outcomes of interest will include readmission, reoperation, and revision (removal of implant).
- The project will look at 90 day, 1 year, and 2 year post-surgery data, as available from collaborators.

National Evaluation System for health Technology Coordinating Center

NESTcc has established relationships with network collaborators to advance evaluation and use of high-quality RWD from various sources.



TO DATE, MEMORANDA OF UNDERSTANDING (MOUS) HAVE BEEN SIGNED WITH 11 COLLABORATORS:

Duke University Health System • Healthcore • Lahey Clinic • Mayo Clinic • MDEpiNet • Mercy Health • PEDSnet • University of Florida Health System • Vanderbilt University Medical Center • Weill-Cornell Medical Center • Yale New Haven Health System



NESTcc surveyed its Data Network to determine current capabilities, gaps, and priority areas.



Collaborators comprising the NESTcc Data Network have access to a range of available data sources, including those listed below.





@NESTccMedTech 📃 www.nestcc.org

Patient-Generated Data

EHR

Leverage

Pharmacies

Public Claims

Private Claims

Registries*



NESTcc will support its Data Network by helping streamline administrative processes, reducing transaction costs, and offering research assistance.



Leverage

REDUCING TRANSACTION COSTS

- Putting in place an umbrella non-disclosure agreement (NDA) with NESTcc Network Collaborators
- Developing a participation agreement defining roles and responsibilities of NESTcc and Network Collaborators
- Developing a Master Services Agreement between the Network Collaborators and the NESTcc to accelerate contracting time



TYPES OF RESEARCH OFFERED

- Prep to research questions (e.g. size and type of patient population with a specific condition or device)
- Identification of patients for clinical trials and identification of clinical trial sites
- Retrospective observational studies with deidentified data
- Prospective observational studies with patient consent
- Patient surveys and patient-generated data with patient consent
- Interventional/randomized studies (not in the short term)

NESTCC DATA NETWORK TIMELINE 2018





NESTCC PROGRESS: A SNAPSHOT





Governing Committee Activity

Seven Governing Committee Meetings Average attendance of 11/15 members per meeting



for health Technology **Social Media Engagement** 80 20000 15000 60 40 10000 20 5000 SEPT '17 LL' NUL 11, NNſ 11, TN 41, 9NV 0CT '17 L1, ΛΟΝ DEC '17 ,17 SEPT '17 17, 11, VON DEC '17 ,17 AUG OCT ٦UL **Twitter Impressions Twitter Followers Events and Conferences 2017 Key Conference Presentations** September RAPS IMDRF Open Stakeholder Day NIH Grand Rounds AdvaMed MedTech Conference MDIC Annual Public Forum October MDEpiNet Annual Meeting ICHOM November • TCT 2017 **Upcoming Events and Conferences** Confirmed • Health Datapalooza – April 26-27, 2018 FDA/Xavier MedCon Conference – May 1-4, 2018

• ISPOR Baltimore – May 19-23, 2018

Submitted

- Academy Health 2018 ARM June 24-26, 2018
- RAPS Regulatory Convergence 2018 October 1-4, 2018







